Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor.
- Author:
Dong Hoe KOO
1
;
Min Hee RYU
;
Kyoung Mee KIM
;
Han Kwang YANG
;
Akira SAWAKI
;
Seiichi HIROTA
;
Jie ZHENG
;
Bo ZHANG
;
Chin Yuan TZEN
;
Chun Nan YEH
;
Toshirou NISHIDA
;
Lin SHEN
;
Li Tzong CHEN
;
Yoon Koo KANG
Author Information
- Publication Type:Original Article
- Keywords: Guideline; Gastrointestinal stromal tumors; Imatinib mesylate; Sunitinib; Regorafenib
- MeSH: Asian Continental Ancestry Group*; China; Consensus*; Diagnosis*; Gastrointestinal Stromal Tumors*; Gastrointestinal Tract; Humans; Imatinib Mesylate; Korea; Medical Oncology
- From:Cancer Research and Treatment 2016;48(4):1155-1166
- CountryRepublic of Korea
- Language:English
- Abstract: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors originating in the gastrointestinal tract. With the introduction of molecular-targeted therapy for GISTs which has yielded remarkable outcomes, these tumors have become a model of multidisciplinary oncological treatment. Although Western clinical guidelines are available for GISTs, such as those published by the National Comprehensive Cancer Network (NCCN) and the European Society of Medical Oncology (ESMO), the clinical situations in Asian countries are different from those in Western countries in terms of diagnostic methods, surgical approach, and availability of new targeted agents. Accordingly, we have reviewed current versions of several GIST guidelines published by Asian countries (Japan, Korea, China, and Taiwan) and the NCCN and ESMO and discussed the areas of dissensus. We here present the first version of the Asian GIST consensus guidelines that were prepared through a series of meetings involving multidisciplinary experts in the four countries. These guidelines provide an optimal approach to the diagnosis and management of GIST patients in Asian countries.
